Key Takeaways:
CVRx shares plunged 59% on Aug. 7 after the heart-failure device maker disclosed a U.S. Department of Justice probe and cut its 2026 revenue guidance.
"We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer," Reed Kathrein, the Hagens Berman partner leading the firm's investigation, said.
CVRx received the Civil Investigative Demand on May 14, 2026, examining whether the company caused false claims to government health programs by improperly marketing Barostim, its FDA-approved implantable neuromodulation device for heart failure, paying kickbacks to providers, or submitting false information. The company also revealed its primary Medicare Advantage payer cut 30-day prior authorization approvals to 25% from 80%, while its sales force faced turnover and strained onboarding. Three days after the stock drop, CVRx terminated Chief Revenue Officer Robert John on Aug. 10.
The investigation centers on whether CVRx misled investors about its sales force and reimbursement rates despite repeatedly citing a $10.5 billion market opportunity with less than 1% penetration. Hagens Berman is urging investors with substantial losses to come forward, while whistleblowers with non-public information could receive up to 30 percent of any SEC recovery.
CVRx had assured investors that its growth strategy rested on a largely complete sales force transformation and high approval rates from Medicare Advantage payers. The Aug. 6 disclosures after market close contradicted that picture, revealing sequentially flat growth in sales territories and a collapse in reimbursement approvals.
The 59% decline leaves CVRx facing continued legal costs and potential regulatory penalties that could further erode shareholder value. Investors will watch for the outcome of the DOJ investigation and any additional guidance revisions or management changes.
This article is for informational purposes only and does not constitute investment advice.
